Quantcast
Last updated on May 28, 2012 at 18:09 EDT

Hythiam Announces Presentation at UBS Global Healthcare Services Conference

February 5, 2008
Repost This

Hythiam, Inc. (NASDAQ:HYTM) announced today that Terren Peizer, Chairman and Chief Executive Officer of Hythiam, will present at the UBS Global Healthcare Services Conference on Tuesday, February 12, 2008 at 3:00 p.m. EST. The event will be held February 11-13, 2008 at the Grand Hyatt New York Hotel in New York City.

To access the UBS conference web cast, please visit http://events.streamx.us/us/event/ eventdetails.aspx?id=ubs20080211. Hythiam’s web cast will also be available on its web site at www.hythiam.com, where it will be archived for 14 days following the conference.

About Hythiam®

Hythiam, Inc. provides behavioral health management services to health plans, employers, criminal justice, and government agencies through a network of licensed and company managed providers. The company approaches the management of behavioral health disorders with a focus on using the latest medical and health technology towards improved outcomes and out-patient treatment. Hythiam also researches, develops, licenses and commercializes innovative and proprietary physiological, nutritional, and behavioral treatment programs. Hythiam offers disease management for substance dependence built around its proprietary PROMETA® Treatment Program for alcoholism and dependence to stimulants. The PROMETA® Treatment Program, which integrates behavioral, nutritional, and medical components, is available through both licensed treatment providers and company managed PROMETA® Centers. Hythiam does not practice medicine or manufacture, distribute, or sell any medications and has no relationship with any manufacturers or distributors of medications used in the PROMETA® Treatment Program. For further information, please visit www.hythiam.com.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company’s control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history and lack of statistically significant formal research studies, the risk that treatment protocols might not be effective, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and substantial regulation in the healthcare industry; and additional risks factors as discussed in the reports filed by the company with the Securities and Exchange Commission, which are available on its website at http://www.sec.gov.